Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 2
1974 3
1975 2
1976 3
1977 2
1978 5
1979 3
1981 1
1982 1
1983 1
1984 4
1985 5
1986 5
1987 3
1988 3
1989 1
1990 4
1991 3
1992 3
1993 2
1994 1
1995 1
1996 2
1997 2
1998 3
1999 1
2000 2
2001 4
2002 2
2003 3
2004 4
2005 3
2006 3
2007 3
2008 2
2010 3
2011 3
2012 1
2013 3
2014 2
2016 1
2017 2
2018 4
2019 3
2020 4
2021 5
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. Röth A, et al. Among authors: soret j. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. Blood. 2020. PMID: 31978221 Free PMC article. Clinical Trial.
[Myeloproliferative syndromes].
Soret J, Kiladjian K. Soret J, et al. Rev Prat. 2021 Feb;71(2):e39-e49. Rev Prat. 2021. PMID: 34160990 French. No abstract available.
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R. Risitano AM, et al. Among authors: soret j. Lancet Haematol. 2021 May;8(5):e344-e354. doi: 10.1016/S2352-3026(21)00028-4. Epub 2021 Mar 23. Lancet Haematol. 2021. PMID: 33765419 Clinical Trial.
Francisella tularensis meningitis.
Contentin L, Soret J, Zamfir O, Gontier O, Lherm T, Hamrouni M, Ouchenir A, Monchamps G, Kalfon P. Contentin L, et al. Among authors: soret j. Med Mal Infect. 2011 Oct;41(10):556-8. doi: 10.1016/j.medmal.2011.07.004. Epub 2011 Aug 9. Med Mal Infect. 2011. PMID: 21831551 No abstract available.
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Röth A, Ichikawa S, Ito Y, Kim JS, Nagy Z, Obara N, Panse J, Schrezenmeier H, Sica S, Soret J, Usuki K, Yoon SS, Balachandran N, Buri M, Lundberg P, Patel H, Shinomiya K, Sostelly A, Nishimura JI. Röth A, et al. Among authors: soret j. Eur J Haematol. 2023 Aug;111(2):300-310. doi: 10.1111/ejh.14011. Epub 2023 Jun 15. Eur J Haematol. 2023. PMID: 37321625 Clinical Trial.
SR proteins as potential targets for therapy.
Soret J, Gabut M, Tazi J. Soret J, et al. Prog Mol Subcell Biol. 2006;44:65-87. doi: 10.1007/978-3-540-34449-0_4. Prog Mol Subcell Biol. 2006. PMID: 17076265 Review.
[Vesicoprostatic sarcomas].
Colombeau P, Marcou AP, Dumas JP, Fabre MC, Soret JY. Colombeau P, et al. Among authors: soret jy. Ann Urol (Paris). 1984 May;18(3):200-3. Ann Urol (Paris). 1984. PMID: 6529226 French.
120 results